MTP4274B - Boron-iodine 124 compounds and their use in bnct with dosimetry - Google Patents

Boron-iodine 124 compounds and their use in bnct with dosimetry

Info

Publication number
MTP4274B
MTP4274B MTP0004274A MTP4274A MTP4274B MT P4274 B MTP4274 B MT P4274B MT P0004274 A MTP0004274 A MT P0004274A MT P4274 A MTP4274 A MT P4274A MT P4274 B MTP4274 B MT P4274B
Authority
MT
Malta
Prior art keywords
boron
compounds
bnct
tumor
cell
Prior art date
Application number
MTP0004274A
Inventor
Paola Panichelli
Gianluca Valentini
Original Assignee
Paola Panichelli
Gianluca Valentini
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Paola Panichelli, Gianluca Valentini filed Critical Paola Panichelli
Priority to MTP0004274A priority Critical patent/MTP4274B/en
Publication of MTP4274B publication Critical patent/MTP4274B/en

Links

Landscapes

  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Method for the synthesis of compounds to be used in BNCT and in monitoring the uptake to tumor tissue. The compounds comprise a stable boron containing group and a not stable radioisotopes I 24-Iodine. The key to successful therapy with BNCT is to obtain a high ratio of boron in tumor cells compared to boron in normal cells and in blood, and to have the methods to calculate "in vivo" exactly the quantity of boron up-take in tumor cells. With the compounds of the invention, higher ratios of boron concentration in a target tumor compared to normal tissue may be achieved than with prior art compounds, such as 20:1. In another embodiment there are provided methods of treatments with glioblastoma multiforme cell and with malignant melanomas ( for which it is reported, there currently is no effective therapy), killing tumor cell without adversely affecting the healthy cell.
MTP0004274A 2009-12-31 2009-12-31 Boron-iodine 124 compounds and their use in bnct with dosimetry MTP4274B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
MTP0004274A MTP4274B (en) 2009-12-31 2009-12-31 Boron-iodine 124 compounds and their use in bnct with dosimetry

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MTP0004274A MTP4274B (en) 2009-12-31 2009-12-31 Boron-iodine 124 compounds and their use in bnct with dosimetry

Publications (1)

Publication Number Publication Date
MTP4274B true MTP4274B (en) 2011-07-04

Family

ID=60629306

Family Applications (1)

Application Number Title Priority Date Filing Date
MTP0004274A MTP4274B (en) 2009-12-31 2009-12-31 Boron-iodine 124 compounds and their use in bnct with dosimetry

Country Status (1)

Country Link
MT (1) MTP4274B (en)

Similar Documents

Publication Publication Date Title
MX2012010226A (en) Use of erbb3 inhibitors in the treatment of triple negative and basal-like breast cancers.
NZ590326A (en) Antagonists of activin-actriia and uses for increasing red blood cell levels
BR112013004917A2 (en) systemic allogeneic stem cell therapies for treating diseases in animals.
EA201290846A1 (en) RADIOT THERAPY COMBINED WITH HYPOXIC CELL SENSITIZERS
BRPI0608175A2 (en) method of eliminating heterogeneous or mixed cell population in tumors as well as maytansinoid compounds
MY183661A (en) Treatment of cancer with tor kinase inhibitors
IN2014DN08886A (en)
PH12013500826A1 (en) Means and methods for treating dlbcl
WO2010148390A3 (en) Polyamine transport inhibitors as novel therapeutics
WO2006020722A3 (en) Polymer conjugates of beta-lapachone and beta-lapachone analogs for tumor targeting
EP4640281A3 (en) Inhibition of metastasis by compounds which reduce the persistent part of the voltage-gated sodium channel
MX365007B (en) USE OF LYSOSOMAL LIPASE ACID TO TREAT LYSOSOMAL ACID LIPASE DIFFICIENCY IN PATIENTS.
AU2010300611A8 (en) Hematopoietic stem cells for use in the treatment of a kidney injury
WO2009127669A3 (en) Ido inhibitors and therapeutic uses thereof
WO2001074376A3 (en) Cathepsin inhibitors in cancer treatment
UA104148C2 (en) [4- (5-AMINOMETHYL-2-fluorophenyl) -piperidine-1-yl] - [7-fluorine-1- (2-methoxyethyl) -4-trifluoromethoxy-1H-indol-3-yl] -methanone as an inhibitor FAT CELLS
RU2013131241A (en) COMPOSITIONS CONTAINING PI3K INHIBITOR AND MEK INHIBITOR, AND ALSO THEIR APPLICATION FOR TREATMENT OF CANCER
MY158929A (en) Pharmaceutical combination
MX2007004955A (en) Methods of treating cancer with lipid-based platinum compound formulations administered intraperitoneally.
UA106214C2 (en) Inhibitors of mitosis for increasing apoptosis in therapy
SG179069A1 (en) Cancer stem cell-targeted and drug resistant cancer therapy
NZ587941A (en) Methods to inhibit tumor cell growth by using lansoprazole
MTP4274B (en) Boron-iodine 124 compounds and their use in bnct with dosimetry
Garabalino et al. Boron biodistribution for BNCT in the hamster cheek pouch oral cancer model: Combined administration of BSH and BPA
MX2009011104A (en) Methods for treating neoplasia with combination of chemotherapeutic agents and radiation.